The White House has announced a new agreement with major pharmaceutical companies to significantly reduce the cost of leading anti-obesity medications. Under the deal, some of these drugs could be made available for as low as $149 per month, a major drop from current prices that can exceed $1,000 monthly.

The agreement, reached with Eli Lilly and Novo Nordisk, marks one of the first large-scale federal efforts to make GLP-1 medications more affordable. According to officials, the administration views the initiative as part of a broader strategy to address chronic disease prevention earlier in life, improving long-term health outcomes and reducing costs in Medicare and other public programs.

The move also connects to ongoing federal work on most-favored-nation drug pricing, aimed at aligning U.S. prescription costs with those in other high-income nations. By targeting one of the fastest-growing categories of prescription drugs, this deal could have wide-ranging effects on pricing and coverage negotiations throughout the health system.

Source: National Association of Benefits and Insurance Professionals